TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00699179
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
Study: NCT00735306
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
Study: NCT00735306
Drug: Tarceva
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
Study: NCT03065556
Drug: 188-0551 Solution
Normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution containing active drug
Study: NCT00365248
Drug: Fibrinogen human (TachoSil)
Normalized name: fibrinogen, human / thrombin, human Medicated Patch [TachoSil]
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection of the liver with or without segmental liver transplantation
Study: NCT03934411
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will orally ingest 100 mg tramadol retard actavis
Study: NCT00003709
Drug: carbendazim
Normalized name: Carbendazim
DrugBank: Carbendazim (DB13009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
Study: NCT04082780
Drug: Rifamycin SV MMX
Normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm
Study: NCT03765827
Drug: Vitamine E Acetate
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
Study: NCT03765827
Drug: No application of vitamin E acetate
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E acetate ointment will not be applied in this group
Study: NCT02584920
Drug: HLX01
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02584920
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01238965
Drug: panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT01237782
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
Study: NCT01725243
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
Study: NCT00825721
Drug: LiquiTears
Normalized name: Liquitears
DrugBank: Polyvinyl alcohol (DB11060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 drops applied daily for 360 days
Study: NCT03480009
Drug: Dextromethorphan Hydrobromide
Normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan capsule
Study: NCT03480009
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
Study: NCT04119102
Drug: Duobrii
Normalized name: Duobrii
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
Study: NCT00637572
Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
Study: NCT03518320
Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
Study: NCT03518320
Drug: Nivolumab Injection [Opdivo]
Normalized name: nivolumab Injection [Opdivo]
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
Study: NCT00637572
Drug: Megestrol acetate oral suspension 40 mg/mL
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
Study: NCT00604617
Drug: RT-23
Normalized name: MRT-2359
DrugBank: MRT-2359 (DB18015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TST - tuberculin skin test
Study: NCT01042652
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegarvir 400mg bid
Study: NCT01371656
Drug: levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT02495493
Drug: Induction DCS chemotherapy
Normalized name: DCS
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
Study: NCT00748956
Drug: Low dose NPY
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50nmol, administered intranasally
Study: NCT00748956
Drug: High dose NPY
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100nmol administered intranasally
Study: NCT01831817
Drug: Sodium monofluorophosphate dentifrice
Normalized name: Sodium Monofluorophosphate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium monofluorophospate dentifrice (1000 ppm F)
Study: NCT01831817
Drug: Sodium Fluoride dentifrice
Normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dentifrice containing 1100ppm F as sodium fluoride
Study: NCT00785486
Drug: Midazolam Alone
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
Study: NCT00785486
Drug: Qualaquin (quinine) alone steady state
Normalized name: quinine Oral Capsule [Qualaquin]
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
Study: NCT00785486
Drug: Midazolam and Qualaquin at steady state
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
Study: NCT00139568
Drug: Tegaserod
Normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00428207
Drug: Insulin Aspart versus Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
Study: NCT00428207
Drug: Insulin Lispro versus Insulin Aspart
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
Study: NCT01294163
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled xenon, maximal inspired concentration of 65%.
Study: NCT01294163
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled sevoflurane, maximal inspired concentration of 1.8%.
Study: NCT01294163
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hourly dose of 2-4 mg/kg
Study: NCT00206934
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
Study: NCT00206934
Drug: escitaolpram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
Study: NCT02988063
Drug: Polidocanol Endovenous Microfoam (PEM)
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Study: NCT02388997
Drug: omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
Study: NCT02961426
Drug: sofosbuvir + ravidasvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: combination of sofosbuvir + ravidasvir
Study: NCT01524081
Drug: Metronidazole, Cefuroxime
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. - Cefuroxime in 100ml saline~2. - Metronidazole in 500ml saline
Study: NCT01524081
Drug: Amoxicillin (+ clavulanic acid) and Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~1. - 2x amoxicillin in 100ml saline~2. - Fluconazole in 500ml saline
Study: NCT01764607
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
Study: NCT00083928
Drug: Å6 subcutaneous injection
Normalized name: Chlorin a6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00712582
Drug: Etoposide, carboplatin, ifosfamide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
Study: NCT00712582
Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
Study: NCT00712582
Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital.
Study: NCT00491374
Drug: Mometasone Furoate Nasal Spray
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
Study: NCT02539511
Drug: CI-581a
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02539511
Drug: CI-581b
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006184
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
Study: NCT00006184
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
Study: NCT00006184
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3
Study: NCT00006184
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )
Study: NCT00006184
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 day 1-4
Study: NCT00006184
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3
Study: NCT03440879
Drug: Zoladex
Normalized name: Zoladex
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients currently treated with Zoladex
Study: NCT00094432
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
Study: NCT01877889
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).
Study: NCT01877889
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
Study: NCT01493856
Drug: Cresto
Normalized name: Crestor
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet, rosuvastatin 20mg
Study: NCT01493856
Drug: Olmetec
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, olmesartan medoxomil(CS-866) 40mg
Study: NCT01972789
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
Study: NCT01853956
Drug: Alprazolam 0.25 mg
Normalized name: alprazolam 0.25 MG
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference product
Study: NCT01853956
Drug: Alprazolam 0.25 mg
Normalized name: alprazolam 0.25 MG
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test product
Study: NCT02985242
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin film-coated tablet
Study: NCT02985242
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride tablet
Study: NCT02985242
Drug: Empagliflozin placebo
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
Study: NCT02985242
Drug: Glimepiride placebo
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
Study: NCT00835497
Drug: 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 x 5 mg/500 mg, single-dose fasting
Study: NCT02859896
Drug: Doxercalciferol (GZ427397)
Normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT02859896
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT01286571
Drug: BI 135585
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one oral single dose per subject
Study: NCT03914677
Drug: Mecamylamine Oral Tablet
Normalized name: mecamylamine Oral Tablet
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nicotinic antagonist (ganglionic blocker)
Study: NCT01246206
Drug: Tacrolimus and Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours.
Study: NCT01873248
Drug: 68Ga-DOTATATE
Normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
Study: NCT04383938
Drug: APR-246 (eprenetapopt) + Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: APR-246 D1-4 + Pembrolizumab D3
Study: NCT04065919
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
Study: NCT03022617
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00448422
Drug: prulifloxacin
Normalized name: prulifloxacin
DrugBank: Prulifloxacin (DB11892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00121628
Drug: AMG 706
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00447122
Drug: Gemcitabine 1000mg/m2 30 minutes
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 30 minutes
Study: NCT00447122
Drug: Lapatinib 1000mg/d
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000mg/d
Study: NCT00447122
Drug: Lapatinib 1500mg/d
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1500mg/d
Study: NCT00447122
Drug: Gemcitabine 1000mg/m2 100minutes
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 100minutes
Study: NCT00447122
Drug: Oxaliplatin 100mg/m2
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/m2
Study: NCT01826175
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
Study: NCT01826175
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
Study: NCT02023047
Drug: Nifedipine 12 mg coated suppositories
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03000036
Drug: Gadoterate Meglumine
Normalized name: Gadoterate meglumine
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).